Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
For Researchers | Link your sites and fill your trials
Our website attracts 120,000 patients annually seeking information on treatments and clinical trials. We facilitate direct connections between these patients and trial organizers through our Clinical Trials page, which features verified study details.
However, we recognize that some participating sites face challenges in recruiting sufficient participants due to limited visibility. To address this, we offer a complimentary service to highlight these sites in our announcements, complete with direct contact information for each specific location. This additional exposure aims to boost recruitment efforts at no extra cost to researchers.
FAQOther Questions
- I have vitiligo: will my children have vitiligo, too?
If you have vitiligo, it’s natural to worry about your children. While there is a genetic component, vitiligo is not a straightforward hereditary disease like eye color or heigh...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Is there a special diet for vitiligo?
Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.